Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety,
tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in
asthmatic and chronic obstructive pulmonary disease (COPD) subjects.